Claims for Patent: 12,156,869

Summary for Patent: 12,156,869

Title:	Losartan liquid formulations and methods of use
Abstract:	The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.
Inventor(s):	Bhavya Teja KOLLA, Rahul Surana, Suketu Sanghvi, Jigar BHATT
Assignee:	Meds Merger Sub Ii LLC , Scienture LLC
Application Number:	US18/421,405
Patent Claims:	1. A method of treating a disease or condition responsive to angiotensin II receptor inhibition comprising administering to a subject in need thereof a therapeutically effective amount of an oral pharmaceutical composition comprising: i.) about 1 mg/mL to about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof, ii.) about 0.5 mg/mL to about 1.5 mg/mL of a suspending agent selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, acacia, an alginate, and guar gum, or a combination thereof, iii.) a pH modifying agent, iv.) about 0.1 mg/mL to about 3 mg/mL of a preservative, v.) one or more solubilizers selected from the group consisting of cremophor, vitamin E, polyethylene glycol, propylene glycol, and co-solvent, or a combination thereof, vi.) a crystallization inhibitor comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, or both; and wherein the pharmaceutical composition is a suspension, wherein the suspension has a pH of about 7, and wherein after 12 months of storage at 40° C. at 75% relative humidity, the suspension comprises at least 95% of the losartan that was in the suspension prior to storage. 2. The method of claim 1, further comprising one or more pharmaceutically acceptable excipients selected from the group consisting of an emulsifying agent, an antioxidant, a chelating agent, a surfactant or wetting agent, a sweetener, a stabilizer, a flavoring agent, and a colorant. 3. The method of claim 1, wherein the pH modifying agent is selected from the group consisting of citric acid, sodium citrate, acetic acid, sodium acetate, sodium hydroxide, sodium dihydrogen phosphate, and disodium hydrogen phosphate. 4. The method of claim 1, wherein the oral pharmaceutical composition comprises about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein the preservative is selected from the group consisting of methyl paraben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid, sodium benzoate, and benzalkonium chloride, or a combination thereof. 6. The method of claim 1, wherein the oral pharmaceutical composition further comprises about 20 mg/mL to about 30 mg/mL polyethylene glycol and one or more of about 20 mg/mL to about 30 mg/mL propylene glycol, about 0.3 mg/mL to about 1.2 mg/mL sodium phosphate monobasic and one or more of about 0.5 mg/mL to about 1.5 mg/mL sodium phosphate dibasic, and a mint flavor in an amount less than 10 wt/wt %. 7. The method of claim 1, wherein the suspending agent comprises xanthan gum. 8. The method of claim 1, wherein the oral pharmaceutical composition further comprises an antifoaming agent comprising simethicone emulsion. 9. The method of claim 1, wherein the oral pharmaceutical composition further comprises about 10 mg/mL to about 20 mg/mL polyvinylpyrrolidone, about 1 mg/mL to about 2.5 mg/mL xanthan gum, about 5 mg/mL to about 10 mg/mL simethicone emulsion, and sucralose in an amount less than 1 wt/wt %. 10. The method of claim 1, wherein the subject is a human. 11. A method of treating a disease or condition responsive to angiotensin II receptor inhibition comprising administering to a subject in need thereof a therapeutically effective amount of an oral pharmaceutical composition comprising: i.) about 1 mg/mL to about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof, ii.) about 0.5 mg/mL to about 1.5 mg/mL of a suspending agent selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, acacia, an alginate, and guar gum, or a combination thereof, iii.) about 0.5 mg/mL to about 1.5 mg/mL of a pH modifying agent, iv.) about 5 mg/mL to about 15 mg/mL of a crystallization inhibitor comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, or both, v.) about 0.1 mg/mL to about 3 mg/mL of a preservative, vi.) about 1 mg/mL to about 10 mg/mL of an antifoaming agent, and vii.) about 20 mg/mL to about 60 mg/mL of a solubilizer selected from the group consisting of cremophor, vitamin E, polyethylene glycol, propylene glycol, and co-solvent, or a combination thereof; wherein the pharmaceutical composition is a suspension, wherein the suspension has a pH of about 7, and wherein after 6 months of storage at 40° C. at 75% relative humidity, the suspension comprises at least about 97% of the amount of losartan in the suspension prior to storage, after 12 months of storage at 40° C. at 75% relative humidity, the suspension comprises at least about 98% of the amount of losartan in the suspension prior to storage, or after 12 months of storage at 40° C. at 75% relative humidity, the suspension comprises at least about 99% of the amount of losartan in the suspension prior to storage. 12. The method of claim 11, wherein the oral pharmaceutical composition comprises about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof. 13. The method of claim 11, wherein the pharmaceutically acceptable salt is losartan potassium. 14. The method of claim 11, wherein the oral pharmaceutical composition comprises one or more pharmaceutically acceptable excipients selected from the group consisting of an emulsifying agent, an antioxidant, a chelating agent, a surfactant or wetting agent, a sweetener, a stabilizer, and a flavoring agent. 15. The method of claim 11, wherein after 6 months of storage at 40° C. at 75% relative humidity, the suspension comprises less than about 2 wt/wt % losartan impurity D and losartan impurity E, relative to the weight of losartan in the suspension; or wherein after 12 months of storage at 40° C. at 75% relative humidity, the suspension comprises less than about 1 wt/wt % losartan impurity D and losartan impurity E, relative to the weight of losartan in the suspension; or wherein after 12 months of storage at 40° C. at 75% relative humidity, the suspension comprises less than about 0.5 wt/wt % losartan impurity D and losartan impurity E, relative to the weight of losartan in the suspension. 16. A method of treating a disease or condition responsive to angiotensin II receptor inhibition comprising administering to a subject in need thereof a therapeutically effective amount of an oral pharmaceutical composition comprising: i.) about 1 mg/mL to about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof, ii.) a suspending agent, iii.) a pH modifying agent, and iv.) a preservative, v.) one or more solubilizers selected from the group consisting of cremophor, vitamin E, polyethylene glycol, propylene glycol, and co-solvent, or a combination thereof, vi.) a crystallization inhibitor comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, or both; and wherein the pharmaceutical composition is a suspension, wherein the suspension has a pH of about 7, and wherein after 12 months of storage, the suspension comprises at least 95% of the losartan that was in the suspension prior to storage. 17. The method of claim 16, further comprising one or more pharmaceutically acceptable excipients selected from the group consisting of an emulsifying agent, an antioxidant, a chelating agent, a surfactant or wetting agent, a sweetener, a stabilizer, a flavoring agent, and a colorant. 18. The method of claim 16, wherein the pH modifying agent is selected from the group consisting of citric acid, sodium citrate, acetic acid, sodium acetate, sodium hydroxide, sodium dihydrogen phosphate, and disodium hydrogen phosphate. 19. The method of claim 16, wherein the oral pharmaceutical composition comprises about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof. 20. The method of claim 16, wherein the preservative is selected from the group consisting of methyl paraben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid, sodium benzoate, and benzalkonium chloride, or a combination thereof. 21. The method of claim 16, wherein the oral pharmaceutical composition further comprises about 20 mg/mL to about 30 mg/mL polyethylene glycol and one or more of about 20 mg/mL to about 30 mg/mL propylene glycol, about 0.3 mg/ml to about 1.2 mg/mL sodium phosphate monobasic and one or more of about 0.5 mg/mL to about 1.5 mg/mL sodium phosphate dibasic, and a mint flavor in an amount less than 10 wt/wt %. 22. The method of claim 16, wherein the suspending agent comprises xanthan gum. 23. The method of claim 16, wherein the oral pharmaceutical composition further comprises an antifoaming agent. 24. The method of claim 16, wherein the oral pharmaceutical composition further comprises about 10 mg/mL to about 20 mg/mL polyvinylpyrrolidone, about 1 mg/mL to about 2.5 mg/mL xanthan gum, about 5 mg/mL to about 10 mg/mL simethicone emulsion, and sucralose in an amount less than 1 wt/wt %. 25. The method of claim 16, wherein the subject is a human.